• ВПЧ-тестирование в цервикальном скрининге
ru К содержанию

ВПЧ-тестирование в цервикальном скрининге

HEALTH OF WOMAN. 2016.6(112):100–102; doi 10.15574/HW.2016.112.100 

ВПЧ-тестирование в цервикальном скрининге 

Рыкова О. В.

Медицинская лаборатория «Синэво», г. Киев 

В статье представлены современные лабораторные аспекты цервикального скрининга, включающие оценку инфицирования вирусом папилломы человека (ВПЧ) высокого канцерогенного риска.

Ключевые слова: рак шейки матки, цервикальный скрининг, традиционная цитология, жидкостная цитология, ПАП-тест, вирус папилломы человека.


1. Wright TC, Stoler MH, Sharma A et al. 2011. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol 136:578–586. http://dx.doi.org/10.1309/AJCPTUS5EXAS6DKZ; PMid:21917680

2. FDA Approves First Human Papillomavirus Test for Primary Cervical Cancer Screening. News. Silver Spring, Md: Food and Drug Administration, 2014. Available online. Last accessed September 18, 2014.

3. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S et al. 2006. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119:1095–101. http://dx.doi.org/10.1002/ijc.21955; PMid:16586444

4. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. 2011. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 128:927–35. http://dx.doi.org/10.1002/ijc.25396; PMid:20473886

5. Bulk S, Visser O, Rozendaal L, Verheijen RH, Meijer CJ. 2003. Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area. Br J Cancer 89:834–9. http://dx.doi.org/10.1038/sj.bjc.6601157; PMid:12942114 PMCid:PMC2394479

6. Confortini M, Bergeron C, Desai M, Negri G, Dalla PP, Montanari G et al. 2010. Accuracy of liquid-based cytology: comparison of the results obtained within a randomized controlled trial (the New Technologies for Cervical Cancer Screening Study) and an external group of experts. Cancer Cytopathol 118:203–8. http://dx.doi.org/10.1002/cncy.20081; PMid:20731006

7. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–9. http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F

8. Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-Luthge A, Bergeron C et al. 2011. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-staine cytology. Gynecol Oncol.

9. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D et al. 2004. Against which human papillomavirus types shall we vaccinate and screen? the international perspective. Int J Cancer 111:278–85. http://dx.doi.org/10.1002/ijc.20244; PMid:15197783

10. Overmeer RM, Henken FE, Bierkens M, Wilting SM, Timmerman I, Meijer CJ et al. 2009. Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis. J Pathol 219:327–36. http://dx.doi.org/10.1002/path.2598; PMid:19662663

11. European Commission. European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd ed. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H, Herbert A, Daniel J, von Karsa L, European Commission, editors. Luxembourg: Office for Official Publications of the European Communities, 2008: 1–291.

12. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. 2006. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24 (3):S78–S89. http://dx.doi.org/10.1016/j.vaccine.2006.05.117; PMid:16950021